Tryptase βII (human), (recombinant)



BML-SE418-0020	20 µg	Inquire for pricing
Do you need bulk/larger quantities?

Product Details

Alternative Name:	Tryptase β-2, TPSβ2, Tryptase-2

MW:	~35kDa (under reducing conditions); ~140kDa (tetramer under non-reducing conditions).

Source:	Produced in yeast.

EC:	3.4.21.59

UniProt ID:	P20231

Formulation:	Liquid. In 10mM MES (2-[N-morpholino]ethanesulfonic acid), pH 6.1, containing 2M sodium chloride. This preparation does not contain heparin, a poly-negative molecule which can alter assay outcomes or interfere with inhibitors. Stabilized with 2M NaCl in the storage buffer, but dilution will reduce stability.

Purity:	≥90% (SDS-PAGE)

Specific Activity:	1000 U/mg, where one unit yields an absorbance change of 1 OD/minute at 410 nm using as substrate 400μM CBZ-L-lysine thiobenzyl ester coupled with 0.5mM DTNB at 25°C.

Application Notes:	Useful tool to study enzyme kinetics, cleave target substrates, and screen for inhibitors.

Shipping:	Dry Ice

Long Term Storage:	-20°C

Use/Stability:	-20°C for at least six months. The enzyme is stable as supplied on ice for at least several days. However, it is recommended that dilution of the enzyme, and its stabilizer NaCl, be done within as short a time as possible before start of the assay. After initial defrost, aliquot product into individual tubes and refreeze at -20°C. It can be freeze/thawed at least 4 times, but avoid repeated freeze/defrost cycles.

Handling:	Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.

Scientific Background:	βII-tryptase, also known as β-tryptase or tryptase II, is a glycosylated trypsin-like neutral serine endopeptidase. Like the closely-related tryptase-α, -β1, and -β3, it forms tetramers that are stored in mast cell secretory granules until release. Its physiological targets include pro-MMP-3, vasoactive intestinal peptide (VIP), and fibronectin. It is believed to be involved in tissue and wound remodeling, and inflammatory and allergic processes, making it a target for drug discovery in these areas.

Technical Info/Product Notes:	It is recommended that enzyme inhibitor assays be done in the manner of Mecca et al. (see reference). If long incubation times are necessary, heparin (50-100μg/ml final) or dextran sulfate can be added. Also available is substrate Z-GPR-AMC (Prod. No. BML-P142).

Regulatory Status:	RUO - Research Use Only

General Literature References

Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense: H.P. McNeil, et al.; J. Biol. Chem. 282, 20785 (2007), Abstract;

Structural requirements and mechanism for heparin-dependent activation and tetramerization of human betaI- and betaII-tryptase: J. Hallgren, et al.; J. Mol. Biol. 345, 129 (2005), Abstract;

Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase: J. Levell, et al.; Bioorg. Med. Chem. 13, 2859 (2005), Abstract;

Designed calix[8]arene-based ligands for selective tryptase surface recognition: T. Mecca, et al.; Bioorg. Med. Chem. 12, 5057 (2004), Abstract;

Mast cell tryptase, a still enigmatic enzyme: L. Fiorucci & F. Ascoli; Cell. Mol. Life Sci. 61, 1278 (2004), Abstract;

Definition of the extended substrate specificity determinants for beta-tryptases I and II: J.L. Harris, et al.; J. Biol. Chem. 276, 34941 (2001), Abstract;